Rini BI, Pal SK, Escudier BJ, et al. - By performing an open-label, randomised, controlled trial, TIVO-3, researchers compared tivozanib (a potent and selective VEGF receptor inhibitor) vs sorafenib in terms of efficacy and safety as third-line or fourth-line treatment in patients with metastatic renal cell carcinoma. This inquiry was held at 120 academic hospitals in 12 countries. Cases previously treated with tivozanib or sorafenib were excluded. Overall 350 patients were randomized (1:1) to either tivozanib 1·5 mg orally once daily in 4-week cycles or sorafenib 400 mg orally twice daily continuously. The participants were stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk category and type of prior treatment. Improvement in progression-free survival was brought about by tivozanib as third-line or fourth-line therapy and it was better tolerated vs sorafenib in patients with metastatic renal cell carcinoma.